ArticleCureus2025
Concurrent Radiation With Nivolumab and Chemotherapy for Nodal-Only Distant Metastatic Stage IV Esophageal Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical response rates for patients with stage IV human epidermal growth factor receptor 2 (HER2) negative esophageal carcinoma treated with immunotherapy and chemotherapy remain low, around 10%. HER2 is a protein that is found on the surface of a cell, including cancer cells. This receptor can sometimes be targeted to help eradicate the cancer cell. Immunotherapy is a type of treatment that stimulates the immune system to eradicate other cancer cells in the body. Cancer cells often have a protein on their surface called programmed cell death ligand 1 (PD-L1). This protein binds to the programmed cell death 1 (PD-1) protein that is on white blood cells. The binding of these two proteins prevents the white blood cell from eradicating the cancer cell. Immunotherapy prevents the binding of these proteins and thus increases the chances of the white blood cell eliminating the cancer cell. The addition of concurrent radiation could improve this response rate by direct cell kill, increase the immunotherapy response via the abscopal effect, and eliminate micro-metastatic cancer. Obtaining a complete clinical response could be a prognostic marker for improved outcomes. A complete clinical response is where the imaging scans and/or direct visual examination of certain parts of the body show no evidence of cancer. We now present a unique case of concurrent radiation with nivolumab and chemotherapy for a distant nodal-only metastatic stage IV esophageal patient who obtained a complete clinical response within three months of his last radiation treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.